Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates
Walser, M.; Rothenberger, S.; Hurdiss, D. L.; Schlegel, A.; Calabro, V.; Fontaine, S.; Villemagne, D.; Paladino, M.; Hospodarsch, T.; Neculcea, A.; Cornelius, A.; Schildknecht, P.; Matzner, M.; Haenggi, M.; Franchini, M.; Kaufmann, Y.; Schaible, D.; Schlegel, I.; Iss, C.; Looser, T.; Mangold, S.; Herzog, C.; Schiegg, D.; Reichen, C.; Radom, F.; Bosshart, A.; Lehmann, A.; Haeuptle, M. A.; Zuercher, A.; Vagt, T.; Sigrist, G.; Straumann, M.; Proba, K.; Veitonmaki, N.; Dawson, K. M.; Zitt, C.; Mayor, J.; Ryter, S.; Lyoo, H.; Wang, C.; Li, W.; Drulyte, I.; Du, W.; Binz, H. K.; de Waal, L.; Stittela
Show abstract
Globally accessible therapeutics against SARS-CoV-2 are urgently needed. Here, we report the generation of the first anti-SARS-CoV-2 DARPin molecules with therapeutic potential as well as rapid large-scale production capabilities. Highly potent multivalent DARPin molecules with low picomolar virus neutralization efficacies were generated by molecular linkage of three different monovalent DARPin molecules. These multivalent DARPin molecules target various domains of the SARS-CoV-2 spike protein, thereby limiting possible viral escape. Cryo-EM analysis of individual monovalent DARPin molecules provided structural explanations for the mode of action. Analysis of the protective efficacy of one multivalent DARPin molecule in a hamster SARS-CoV-2 infection model demonstrated a significant reduction of pathogenesis. Taken together, the multivalent DARPin molecules reported here, one of which has entered clinical studies, constitute promising therapeutics against the COVID-19 pandemic.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy 96%
- Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19 94%
- Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases 93%
Similar papers in this journal
- Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors 96%
- Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 95%
- SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface 94%
Similar papers in this journal
Similar papers in this journal
- Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative 95%
- Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 94%
- Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.